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CONCLUSIONS: Regardless of LVERSUSF, prescribed
drug therapies at discharge were similar among patients
hospitalized for CHF in the hospital. Findings indicate a
need to better understand the role and actual implemen-
tation of guidelines that recommend customized CHF
drug therapy tailored to LVERSUSF.
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OBJECTIVES: The GOALS (Gauging Overall Attain-
ment of Lipid Standards) study, a retrospective chart re-
view of 1727 geographically diverse US adult patients
with hyperlipidemia, examined the extent to which pa-
tients met National Cholesterol Education Program
(NCEP) guidelines after treatment with various HMG-
CoA reductase inhibitors (“statins”).
METHODS: For this study 1500 physicians (family prac-
titioners and cardiologists) were randomly selected from
national lists. Forty-five physicians (37 FPs, 8 cardiolo-
gists) provided data on at least 40 hyperlipidemic pa-
tients. Each physician was asked to abstract data from
the medical charts of at least 10 atorvastatin patients, 10
simvastatin patients, and 20 patients who received any
statin between January 1996 and June 1998.
RESULTS: Patients were aged 20–96, 52% female, and
87% white. The most common primary prevention risk
factors were age (73%) and hypertension (58.8%). There
were no statistically significant differences in gender,
race, age at diagnosis, or source of reimbursement be-
tween patients using atorvastatin (n  195), simvastatin
(n  389), pravastatin (n  156), other statins (n  206),
or patients using various statins serially over the time pe-
riod (n  781). Similarly, there were no statistically sig-
nificant differences between the patients in these groups
in terms of secondary prevention risk factors (previous
myocardial infarction [MI], coronary artery disease
[CAD], peripheral vascular disease [PVD], or coronary
vascular disease [CVD]). Patients treated with atorva-
statin alone were significantly more likely to reach the
NCEP LDL-C treatment goal in a shorter time span (log-
rank test chi-square 52.20, p  0.0001).
CONCLUSIONS: This retrospective analysis reinforces
recent randomized trials suggesting hyperlipidemic pa-
tients using atorvastatin may be more likely to reach
NCEP LDL-C treatment goals faster than those using
other statins. Further analysis of patients using combina-
tion therapy is required.
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OBJECTIVE: The purpose of this study was to develop a
method of value analysis which would facilitate an objec-
tive comparison of available angiotensin II antagonists as
blood pressure lowering agents, in order to provide an
adaptable framework to allow for future clinical develop-
ments and new product introduction.
METHODS: The four angiotensin II antagonists avail-
able for analysis were candesartan, irbesartan, losartan,
and valsartan. The analysis was conducted under the aus-
pices of a team comprised of a cardiologist, a physician
and a pharmacist; the pharmacist was responsible for co-
ordination of the process. A nine-point selection criteria
set was developed and each criterion assigned a relative
weight value by the team. Each drug product was system-
atically evaluated against each criterion to generate a se-
ries of product-criterion scores. A total score for each
product was derived from the sum of product-criterion
score multiplied by the respective criterion weighted
value determined previously. The results were analyzed
and the model tested for sensitivity to parameter changes
where any doubts existed concerning the scoring process.
Results and outcomes were presented to the Drug and
Therapeutics Committee.
RESULTS: The initial analysis generated scores which
were similar for irbesartan (831) and candesartan (822).
These scores appeared to be significantly higher than
those obtained for valsartan (764) and losartan (706).
Following consideration of the impact of sensitivity tests
in the model, it had been previously decided that changes
in parameters reflecting efficacy were warranted and so
revised scores for candesartan (901) and irbesartan (871)
were calculated.
CONCLUSIONS: The results were presented to the Drug
and Therapeutics Committee and consequently the addi-
tion of candesartan and removal of losartan from the for-
mulary were formally approved.
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OBJECTIVE: The study purpose was to evaluate the
utility of a patient and prescriber program to increase the
use of antilipemics and/or estrogen in at-risk members
for CAD.
METHODS: Prescription claims from two employer
groups were screened to identify surrogate risk factors
for the development of CAD based on: nitrates, diabetic
claims, tobacco cessation products, and postmenopausal
women not receiving estrogen or cholesterol-lowering
